rucaparib ok model
Indication: Ovarian cancer, metastatic castration-resistant prostate cancer (mCRPC)
Interactive population pharmacokinetic simulator for rucaparib (Rubraca), an oral PARP inhibitor approved for ovarian cancer and mCRPC. Two-compartment model with covariate effects of creatinine clearance and albumin on clearance. Based on Green et al. Cancer Chemother Pharmacol (2022).
Drug Overview
Clinical Context
- Molecular Target
- PARP (poly ADP-ribose polymerase)
- Drug Class
- PARP Inhibitor
- Therapeutic Area
- Oncology
- Indication
- Ovarian cancer, metastatic castration-resistant prostate cancer (mCRPC)
- Route of Administration
- Oral
Model Information
- Model Type
- 2-compartment oral PopPK
- Category
- PopPK (2-compartment)
- Reference
- Green et al. Cancer Chemother Pharmacol (2022)
This simulator was built from published pharmacometric literature using PKPDBuilder's AI-powered model extraction pipeline.
Pharmacokinetic Parameters
PK Parameters
| Parameter | Value |
|---|---|
| Ka | 1.49 h⁻¹ |
| Q F | 4.42 L/h |
| CL F | 17.2 L/h |
| Vc F | 114 L |
| Vp F | 52.6 L |
Parameters sourced from published population pharmacokinetic models. Values represent typical population estimates; individual patient parameters may vary.
About This Simulator
This interactive pharmacokinetic simulator for rucaparib ok model allows you to explore concentration-time profiles under different dosing scenarios. The underlying PopPK (2-compartment) model characterizes the pharmacokinetics of this parp inhibitor following oral administration.
Use the simulator to visualize key exposure metrics including AUC (area under the curve), Cmax (peak concentration), and Ctrough (trough concentration).
Built with PKPDBuilder — an AI-powered platform that transforms published pharmacometric literature into interactive, deployable Shiny applications. No coding required.
Frequently Asked Questions
What is the rucaparib ok model PK simulator?
This is a free, interactive pharmacokinetic simulator for rucaparib ok model used in Ovarian cancer, metastatic castration-resistant prostate cancer (mCRPC). It allows researchers, pharmacologists, and students to explore concentration-time profiles, dosing regimens, and exposure metrics based on published population PK models.
What drug class does rucaparib ok model belong to?
rucaparib ok model is classified as a PARP Inhibitor that targets PARP (poly ADP-ribose polymerase). It is used in the Oncology therapeutic area.
What route of administration does this model simulate?
This simulator models Oral administration of rucaparib ok model. The pharmacokinetic parameters (absorption rate, bioavailability, volume of distribution) are specific to this route.
What type of PK model is used?
This simulator uses a PopPK (2-compartment) model. Population PK models account for interindividual variability and covariate effects on drug exposure.
Is this simulator free to use?
Yes, all PKPDBuilder simulators are completely free. They are built from published pharmacokinetic literature and are intended for research and educational purposes. No login is required to run simulations.
Can I use this for clinical dosing decisions?
No. This simulator is for research and educational purposes only. It should not be used for clinical decision-making or patient dosing. Always consult the prescribing information and clinical pharmacology guidelines for therapeutic drug use.
What is the half-life of rucaparib ok model?
Based on the published model parameters, the elimination half-life of rucaparib ok model is approximately ~17 h. Note that half-life can vary based on patient-specific factors such as body weight, organ function, and genetic polymorphisms.
What is the clearance of rucaparib ok model?
The clearance (CL) of rucaparib ok model is approximately 17.2 L/h. Clearance represents the volume of plasma from which drug is completely removed per unit time and is a key determinant of drug exposure and steady-state concentrations.
Related Simulators
PopPK of Docetaxel
capecitabine
PBPK-PD of ADCs
Trodelvy PopPK
Unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC), HR+/HER2-negative metastatic breast cancer after endocrine and CDK4/6 inhibitor therapy, and locally advanced or metastatic urothelial cancer; TROP2-directed ADC with SN-38 payload
Datroway PopPK
Locally advanced or metastatic non-squamous NSCLC (TROPION-Lung08), HR+/HER2-low/negative metastatic breast cancer (TROPION-Breast01), and triple-negative breast cancer; TROP2-directed ADC with DXd payload
Enhertu PopPK
HER2-positive breast cancer, gastric/gastroesophageal adenocarcinoma, NSCLC
Ready to Simulate?
Launch the rucaparib ok model simulator to explore dosing scenarios and pharmacokinetic profiles interactively.
🚀 Launch SimulatorComments
⚠️ Disclaimer
This simulator is for research and educational purposes only. It is not intended for clinical decision-making, patient dosing, or therapeutic drug monitoring. Pharmacokinetic parameters are derived from published literature and represent population-level estimates. Individual patient pharmacokinetics may differ significantly. Always consult approved prescribing information and qualified healthcare professionals for clinical decisions.
Powered by PKPDBuilder.com • Free pharmacokinetic simulators for the scientific community